Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Trans Am Clin Climatol Assoc ; 126: 20-45, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26330657

RESUMO

The conquest of pellagra is commonly associated with one name: Joseph Goldberger of the US Public Health Service, who in 1914 went south, concluded within 4 months that the cause was inadequate diet, spent the rest of his life researching the disease, and--before his death from cancer in 1929--found that brewer's yeast could prevent and treat it at nominal cost. It does Goldberger no discredit to emphasize that between 1907 and 1914 a patchwork coalition of asylum superintendents, practicing physicians, local health officials, and others established for the first time an English-language competence in pellagra, sifted through competing hypotheses, and narrowed the choices down to two: an insect-borne infection hypothesis, championed by the flamboyant European Louis Westerna Sambon, and the new "vitamine hypothesis," proffered by Casimir Funk in early 1912 and articulated later that year by two members of the American Clinical and Climatological Association, Fleming Mant Sandwith and Rupert Blue. Those who resisted Goldberger's inconvenient truth that the root cause was southern poverty drew their arguments largely from the Thompson-McFadden Pellagra Commission, which traces back to Sambon's unfortunate influence on American researchers. Thousands died as a result.


Assuntos
Suplementos Nutricionais/história , Pelagra/história , Saccharomyces cerevisiae , United States Public Health Service/história , Vitaminas/história , Suplementos Nutricionais/economia , Custos de Cuidados de Saúde , História do Século XX , Humanos , Estado Nutricional , Pelagra/diagnóstico , Pelagra/mortalidade , Pelagra/prevenção & controle , Pelagra/terapia , Pobreza/história , Fatores de Risco , Resultado do Tratamento , Estados Unidos/epidemiologia , United States Public Health Service/economia , Vitaminas/economia , Vitaminas/uso terapêutico
2.
Am Fam Physician ; 91(10): 692-7, 2015 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-25978198

RESUMO

Common questions that arise regarding treatment of gastroesophageal reflux disease (GERD) include which medications are most effective, when surgery may be indicated, which patients should be screened for Barrett esophagus and Helicobacter pylori infection, and which adverse effects occur with these medications. Proton pump inhibitors (PPIs) are the most effective medical therapy, and all PPIs provide similar relief of GERD symptoms. There is insufficient evidence to recommend testing for H. pylori in patients with GERD. In the absence of alarm symptoms, endoscopy is not necessary to make an initial diagnosis of GERD. Patients with alarm symptoms require endoscopy. Screening for Barrett esophagus is not routinely recommended, but may be considered in white men 50 years or older who have had GERD symptoms for at least five years. Symptom remission rates in patients with chronic GERD are similar in those who undergo surgery vs. medical management. PPI therapy has been associated with an increased risk of hip fracture, hypomagnesemia, community-acquired pneumonia, vitamin B12 deficiency, and Clostridium difficile infection.


Assuntos
Refluxo Gastroesofágico , Inibidores da Bomba de Prótons , Diagnóstico Diferencial , Gerenciamento Clínico , Endoscopia/métodos , Refluxo Gastroesofágico/complicações , Refluxo Gastroesofágico/diagnóstico , Refluxo Gastroesofágico/fisiopatologia , Refluxo Gastroesofágico/terapia , Humanos , Conduta do Tratamento Medicamentoso , Inibidores da Bomba de Prótons/administração & dosagem , Inibidores da Bomba de Prótons/efeitos adversos , Prevenção Secundária/métodos , Avaliação de Sintomas/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA